Anti-NOTCH3 antibody [8G5],Abcam,AB252845
What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Want a custom formulation? This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact [email protected]
Host
Rat
Reactivity
Human
Application
ELISA, WB
Platform ID
BAB841718983

Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Product Specifications
Scientific Background
Specifications
NameAnti-NOTCH3 antibody [8G5]
Cat. No.AB252845
HostRat
IsotypeIgG2a
ReactivityHuman
ApplicationELISA, WB
ClonalityMonoclonal
Clone Number8G5
Concentration1.053 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityIon exchange chromatography
Appearance/FormLiquid
ShippingBlue Ice
FormulationPreservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Storage-20°C
Regulatory StatusResearch Use Only
Scientific Background
Target data Functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination (PubMed : 15350543). Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs (By similarity). See full target information NOTC3_HUMAN
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
Request a product
Please provide the required information below so that we can quickly source your products.
